Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.900% senior notes due 2020, $1.0 billion principal amount of 3.625% senior notes due 2022, $1.75 billion principal amount of 4.050% senior notes due 2025 and $1.75 billion principal amount of 5.200% senior notes due 2045. Proceeds of the offering will be used to fund purchases of shares of Biogen’s common stock pursuant to its $5 billion stock repurchase program and for working capital and other general corporate purposes.  

Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders, including multiple sclerosis, hemophilia, plaque psoriasis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and other conditions. Biogen is focused on discovering and developing new therapies that improve the lives of patients having diseases with high unmet medical needs.

The Davis Polk capital markets team included partner Michael Kaplan and associates Drew Glover and Debora A. Ayoub. Associates David R. Bauer and Bonnie Chen provided intellectual property and technology advice. The tax team included partner Po Sit and associate Dao Fu. Members of the Davis Polk team are based in the New York and São Paulo offices. 

Copy link to share post